August 27, 2025

Newly Published Consensus Guidelines Aim to Ensure Safe and Equitable Delivery of Gene Therapy in Duchenne

PPMD, in collaboration with the Muscular Dystrophy Association (MDA), is proud to share the release of newly published consensus guidelines for the delivery and monitoring of gene therapy in Duchenne muscular dystrophy (Duchenne). Developed in…

Learn More

August 18, 2025

Expanding Leadership, Accelerating Progress

Dear PPMD Community, For more than thirty years, I have had the honor of standing beside you—parents, families, clinicians, researchers, and advocates—united in a single purpose: to end Duchenne and Becker muscular dystrophy, and to…

Learn More

August 14, 2025

Make Your Voice Heard: Support Adding Duchenne to the RUSP

Every year, thousands of newborns in the U.S. are screened for serious conditions whose early detection can change the course of their lives. Right now, we have a chance to ensure Duchenne muscular dystrophy is…

Learn More

August 13, 2025

Solid Biosciences Shares Update on INSPIRE DUCHENNE Trial of SGT-003

Solid Biosciences has shared an update on the company’s Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003 for the treatment of individuals living with Duchenne. SGT-003 is a gene therapy candidate for the treatment of Duchenne…

Learn More

August 12, 2025

Calling All Adults with Duchenne & Becker: Join the 2026 PPMD Adult Advisory Committee (PAAC)

Have you been looking for a way to engage with the community more? Do you have a personal experience that you would like to share with the larger community or through federal and state advocacy…

Learn More

August 4, 2025

Dyne Therapeutics, Inc. announced today FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy

Dyne Therapeutics has announced FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy. This designation reflects encouraging early results from the DELIVER clinical trial, where patients demonstrated sustained functional improvements, such as faster time…

Learn More

August 1, 2025

Watch: Capricor Therapeutics – Regulatory Update & Clinical Insights on Deramiocel for Duchenne Cardiomyopathy

Capricor Therapeutics recently joined PPMD for a community webinar on Tuesday, July 29, 2025 to discuss the current status of Capricor’s Biologics License Application (BLA) for Deramiocel (CAP-1002). We discussed the regulatory implications of a…

Learn More

July 29, 2025

Sarepta to Resume ELEVIDYS Shipments to Ambulatory Patients After FDA Recommends Removal of Voluntary Hold for Ambulatory Population

The U.S. Food and Drug Administration (FDA) has announced that the agency is now recommending the removal of Sarepta Therapeutics’ voluntary hold for ambulatory patients eligible to receive ELEVIDYS. In its own press release, Sarepta…

Learn More

July 23, 2025

FDA Grants Breakthrough Therapy Designation to Avidity’s del-zota

Avidity Biosciences, Inc. today shared that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to del-zota (AOC 1044) for the treatment of Duchenne in individuals amenable to exon 44 skipping.  Del-zota…

Learn More

July 22, 2025

Update on ELEVIDYS Shipments in the U.S.

This evening, Sarepta Therapeutics issued a press release stating that it has voluntarily and temporarily paused all shipments of ELEVIDYS for Duchenne in the United States, effective close of business tomorrow, July 22, 2025. According…

Learn More